Trials / Recruiting
RecruitingNCT07209202
Fructose Intestinal Gluconeogenesis
Fructose Metabolism Effects on the Liver: Unraveling the Role of Defective Intestinal GNG in Individuals With Obesity
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Touro University, California · Academic / Other
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.
Detailed description
Qualified participants will undergo a sugar tolerance test at baseline and then randomized to undergo four separate outpatient tracer/feeding studies in a crossover fashion. After an overnight fast, a six-hour fed tracer study will be initiated, during which participants will consume liquid meals containing stable isotopes at regular intervals and receive other isotopes intravenously. Meal composition will differ only by fructose content (High vs. Low) and tracer (oral vs. intravenous 13C-labeled fructose). Blood and urine samples will be collected frequently throughout the study. Each visit will be performed approximately three weeks apart. Vital signs and anthropometrics will be measured at each clinic visit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | High fructose meal | Liquid meals containing 55% total carbohydrate (16% fructose), 30% fat, 15% protein. |
| OTHER | Low fructose meal | 55% total carbohydrate (6% fructose), 30% fat, 15% protein. |
| OTHER | 13C labeled fructose, oral | Tracer amount of 13C labeled fructose administered orally in the meals. |
| OTHER | 13C labeled fructose, intravenous | Tracer amount of 13C fructose administered intravenously |
Timeline
- Start date
- 2026-03-02
- Primary completion
- 2030-06-01
- Completion
- 2030-06-01
- First posted
- 2025-10-06
- Last updated
- 2026-03-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07209202. Inclusion in this directory is not an endorsement.